As per MRFR analysis, the US Chronic Kidney Disease Market Size was estimated at 8.06 (USD Billion) in 2023. The US Chronic Kidney Disease Market Industry is expected to grow from 8.51(USD Billion) in 2024 to 15 (USD Billion) by 2035. The US Chronic Kidney Disease Market CAGR (growth rate) is expected to be around 5.286% during the forecast period (2025 - 2035).
The US Chronic Kidney Disease (CKD) market is undergoing significant transformation driven by a combination of rising prevalence rates, increasing awareness, and advancements in treatment options. One key market driver is the growing population of patients diagnosed with CKD, which is largely due to factors such as aging demographics and the rise in conditions like diabetes and hypertension, known to contribute to kidney disease. This rise is prompting healthcare providers and policymakers to prioritize interventions that can improve patient outcomes and manage healthcare costs effectively.
Opportunities in the US CKD market are abundant, particularly in the realm of innovative therapies and technology integration.Companies have the potential to explore treatments such as novel pharmaceuticals, kidney transplantation solutions, and home dialysis options, all of which are gaining traction among both healthcare professionals and patients. There is also increasing interest in telehealth services and digital health tools that enable better patient monitoring and engagement. These opportunities align well with the ongoing shift towards value-based care, which emphasizes patient-centric approaches and improved quality of life.
Recent trends in the US CKD market highlight a growing emphasis on preventive care and early diagnosis. There has been a push for routine screening for kidney disease, especially among high-risk populations, allowing for timely intervention that can slow disease progression.Additionally, educational campaigns and community outreach programs are becoming more prominent, aiming to raise awareness of kidney health and encourage lifestyle changes. The integration of artificial intelligence and data analytics in predicting CKD risk and personalizing treatment is also emerging as a significant trend, marking a shift towards more tailored healthcare solutions. This ongoing evolution reflects the commitment to addressing chronic kidney disease more effectively in the US and optimizing patient care.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The increasing prevalence of Chronic Kidney Disease (CKD) in the United States significantly drives the US Chronic Kidney Disease Market Industry. Reports from the Centers for Disease Control and Prevention (CDC) indicate that approximately 15% of adults in the US, which is around 37 million people, are estimated to have some form of CKD. This alarming statistic highlights a growing patient population that requires medical therapies, monitoring, and interventions, thereby expanding market opportunities for pharmaceutical companies and healthcare providers.
As CKD becomes more prevalent, the demand for renal replacement therapies, medications, and overall healthcare services specifically tailored to CKD patients is expected to heighten, fostering considerable growth in the US Chronic Kidney Disease Market. The market is not only influenced by the number of patients suffering from CKD but also by advancements in treatment options and better patient management strategies aimed at improving quality of life and minimizing complications associated with the disease.
Innovative technologies and advancements in treatment modalities such as dialysis and kidney transplantation are pivotal drivers of the US Chronic Kidney Disease Market Industry. Reports indicate that the use of home-based dialysis treatments has increased significantly, providing more convenience and flexibility for patients. The U.S. Renal Data System notes that as of the latest data, about 28% of dialysis patients in the US are using home dialysis, a figure that has steadily increased over the years.
This shift towards at-home therapies not only enhances patient satisfaction but also reduces costs associated with facility-based treatments. The continual investment in Research and Development (R&D) by major players in the healthcare sector further boosts this trend, leading to the continuous introduction of cutting-edge technology and improved therapeutic solutions for CKD patients.
Government initiatives targeting chronic diseases, including Chronic Kidney Disease, significantly foster growth in the US Chronic Kidney Disease Market Industry. The US government has launched various programs aimed at preventive health measures and enhancing kidney health. For example, the National Kidney Foundation engages in public awareness campaigns to educate the population about CKD risk factors and the importance of early detection.
These initiatives are crucial as they facilitate early diagnosis and preventive measures, subsequently reducing the overall healthcare burden and promoting better patient outcomes.The financial support for kidney disease research and patient education advocated by the government guides the development of new treatment options, creating viable paths for market expansion.
There is a notable increase in awareness and screening initiatives for Chronic Kidney Disease within the United States, significantly impacting the US Chronic Kidney Disease Market Industry. Programs introduced by healthcare organizations and advocacy groups promote the importance of regular screening and early diagnosis, as highlighted by the National Kidney Foundation, which estimates that only 10% of people with CKD are aware of their condition.
This knowledge gap is narrowing due to increased educational efforts and community outreach, ultimately leading to more diagnoses and treatment opportunities. The push for greater awareness is generating a greater demand for testing and treatment options in the CKD market, encouraging stakeholders to invest in developing effective screening tools and educational resources.
The Diagnosis segment of the US Chronic Kidney Disease Market has become increasingly significant as the prevalence of chronic kidney disease continues to rise among the population. Driven by factors such as the aging population, the increasing incidence of diabetes and hypertension, and advancements in diagnostic technologies, this segment plays a crucial role in early detection and management of the disease.
Blood Tests are essential as they help in assessing kidney function through parameters such as serum creatinine and blood urea nitrogen levels, making them the primary tool for initial screening and monitoring. Urine Tests, likewise, are vital as they can reveal abnormalities such as proteinuria, which is a key indicator of kidney damage, allowing for timely intervention. Imaging Tests, encompassing ultrasound and CT scans, aid in visualizing structural abnormalities within the kidneys, facilitating further investigation and treatment planning.
Kidney Biopsy remains a definitive method when a precise diagnosis is required, often employed when the etiology of kidney impairment is unclear; this invasive procedure helps in determining the underlying pathology of kidney diseases.Collectively, these diagnostic methods complement one another and provide critical insights into patient health, enabling healthcare providers in the US to formulate effective treatment plans and enhance patient outcomes. The rising adoption of advanced diagnostic modalities is likely to augment overall patient care and healthcare efficiency.
Additionally, the growing awareness and focus on preventive healthcare are driving demand for comprehensive diagnostic services in the US Chronic Kidney Disease Market. As the market continues to mature, the integration of artificial intelligence and telemedicine in diagnostic practices poses new opportunities for optimizing patient management.This spectrum of methodologies not only empowers clinicians but also educates patients, fostering a more informed approach towards kidney health, ultimately aiming to reduce healthcare costs and improve the quality of life for those affected by chronic kidney diseases. Overall, within the context of the US Chronic Kidney Disease Market, the Diagnosis segment serves as a foundation for early intervention, therapeutic decision-making, and is a cornerstone of modern medical practice in addressing this prevalent health challenge.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Treatment segment of the US Chronic Kidney Disease Market serves as a critical area for managing the growing prevalence of kidney-related disorders. With an overall market value expected to reach 8.51 USD Billion by 2024, the demand for effective treatments is supported by the increasing patient population and advancements in medical technologies. Within this segment, Drugs, Dialysis, and Kidney Transplant methods play prominent roles.
Drugs that target symptom alleviation and progression delay are crucial, given the need for long-term management strategies.Dialysis remains a backbone approach, catering to a significant portion of patients who require renal replacement therapy, and is often the primary treatment before a transplant option is considered. Additionally, Kidney Transplants represent a pivotal method, generally sought after for its potential to completely replace kidney function, thus enhancing quality of life. The interplay of these segments highlights a comprehensive approach to treatment and illustrates the dynamics of the US Chronic Kidney Disease Market, with ongoing innovations promising to enhance patient outcomes.
Furthermore, government initiatives and funding for Research and Development in this area lead to enhanced treatments options, thus influencing market growth positively.
The US Chronic Kidney Disease Market is significantly influenced by various indications, with Type 1 and Type 2 diabetes, High Blood Pressure, and Polycystic Kidney Disease playing key roles. Type 1 and Type 2 diabetes are among the leading causes of chronic kidney disease, often leading to elevated healthcare costs and resource utilization. High Blood Pressure also emerges as a major contributor, as it exacerbates kidney dysfunction in many patients.
Polycystic Kidney Disease, a genetic disorder, further complicates the landscape, with a notable prevalence among the US population, leading to considerable treatment advancements.The importance of these indications is underscored by their direct correlation with the growing prevalence of chronic kidney disease, necessitating ongoing research and innovative treatment solutions.
Understanding the US Chronic Kidney Disease Market segmentation helps in addressing the unique requirements of each patient group, driving improved patient care and outcomes while informing the development and implementation of effective management strategies in the industry. The overall healthcare infrastructure in the US must adapt to these challenges, contributing to both the economic burden of chronic diseases and the opportunity for targeted therapies and preventive measures within the healthcare system.
The End User segment of the US Chronic Kidney Disease Market plays a pivotal role in shaping healthcare strategies and patient outcomes. Within this segment, Hospitals and Clinics are critical as they provide comprehensive care, including diagnosis, treatment, and ongoing management of chronic kidney disease. These facilities often serve as the first point of contact for patients and are equipped with specialized resources to manage complex cases effectively.
Diagnostic Centers also hold significant importance, as they offer advanced testing and monitoring services essential for early detection and ongoing assessment of kidney function.The increasing prevalence of chronic kidney disease in the United States underscores the need for these end users to enhance their services and adopt advanced technologies. As awareness around kidney health grows, both Hospitals and Clinics and Diagnostic Centers are expected to evolve, focusing on patient-centric care. This creates opportunities for innovation in treatment modalities, thereby driving further growth in the US Chronic Kidney Disease Market.
The US Chronic Kidney Disease Market is characterized by a diverse array of players, each vying for dominance in a landscape defined by constant innovation and strategic partnerships. Key competitive insights reveal a dynamic market environment shaped by advances in pharmaceuticals, therapeutic solutions, and technologies aimed at improving patient outcomes. Companies are increasingly focusing on tailored treatment options that address the unique needs of chronic kidney disease patients, and there is a strong emphasis on research and development to bring forth innovative therapies.
Regulatory landscapes, payer dynamics, and evolving patient demographics are crucial factors driving competition, with companies investing heavily in clinical trials and collaborations to enhance their market positions. Competitive strategies such as mergers and acquisitions, strategic partnerships, and an aggressive focus on customer engagement are also prevalent, all aimed at capturing a larger share of this growing market.
Genzyme, a notable player within the US Chronic Kidney Disease Market, has established itself as a formidable force through its innovative product offerings and comprehensive patient support services. The company boasts strong research and development capabilities, allowing it to introduce cutting-edge therapies specifically designed for the management of chronic kidney conditions. Genzyme's strengths lie in its ability to form strategic partnerships with healthcare providers and organizations, facilitating an integrated approach to patient care. Furthermore, the company actively engages in educational initiatives and patient outreach programs, enhancing its reputation and visibility within the market. Genzyme's commitment to advancing treatment options for kidney disease patients not only reinforces its position in the industry but also demonstrates its dedication to improving overall patient outcomes across the United States.
Merck represents another significant player in the US Chronic Kidney Disease Market, bringing a wealth of experience and expertise in pharmaceuticals and biotechnology. The company has a robust portfolio of key products and services that cater specifically to the management of chronic kidney disease, including medications that target various aspects of the condition. Merck's extensive market presence is bolstered by its strong financial performance and commitment to ongoing research, which is evident through its active participation in clinical trials and collaborations with academic institutions. The company's strengths lie in its innovative drug development pipeline and its ability to swiftly respond to market needs through agile strategic initiatives. Additionally, Merck has cemented its position in the market through strategic mergers and acquisitions that expand its capabilities and product offerings, ensuring that it remains a key player in the landscape of chronic kidney disease treatment in the United States.
In recent months, the US Chronic Kidney Disease Market has seen significant developments, especially with the increasing focus on innovative therapies and technologies. Companies like DaVita and Fresenius Medical Care continue to expand their dialysis services amid rising patient needs. In September 2023, Amgen announced advancements in its drug pipeline targeting renal health, while Genzyme unveiled a new patient support program designed to enhance treatment compliance.
Furthermore, collaborations between American Renal Associates and various healthcare providers have emerged to optimize patient care pathways. In terms of market valuations, Bristol-Myers Squibb has reported considerable growth in its nephrology-related product sales, indicating a robust demand for kidney disease treatments. Notably, in February 2023, U.S. Renal Care acquired several clinics, enhancing its national footprint and service capabilities. Additionally, Baxter International launched a new home dialysis device in May 2023, contributing to the rising trend towards patient-centric care solutions. The chronic kidney disease market is evolving swiftly, driven by technological innovations and strategic mergers, reflecting ongoing efforts to improve patient outcomes and industry competitiveness.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 8.06(USD Billion) |
| MARKET SIZE 2024 | 8.51(USD Billion) |
| MARKET SIZE 2035 | 15.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.286% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Genzyme, Merck, NxStage Medical, American Renal Associates, DaVita, Fresenius Medical Care, BristolMyers Squibb, Baxter International, Kangaroo Health, U.S. Renal Care, Amgen, Astellas Pharma, Roche, AbbVie |
| SEGMENTS COVERED | Diagnosis, Treatment, Indication, End User |
| KEY MARKET OPPORTUNITIES | Telehealth renal management solutions, Innovative dialysis technologies development, Integrated care models expansion, Personalized medicine advancements, Biomarker discovery for CKD. |
| KEY MARKET DYNAMICS | rising prevalence of diabetes, increasing aging population, advancements in treatment modalities, growing awareness and screening, high healthcare costs |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Chronic Kidney Disease Market is expected to be valued at 8.51 USD Billion in 2024.
By 2035, the US Chronic Kidney Disease Market is projected to reach a value of 15.0 USD Billion.
The expected CAGR for the US Chronic Kidney Disease Market from 2025 to 2035 is 5.286%.
The Kidney Biopsy segment will have the highest value, projected to be 5.5 USD Billion by 2035.
The Blood Test segment is expected to reach 4.5 USD Billion in 2035.
Major players include Genzyme, Merck, NxStage Medical, and DaVita among others.
The Urine Test segment is projected to be valued at 3.0 USD Billion by 2035.
By 2035, the Imaging Test segment is expected to generate a market value of 2.0 USD Billion.
Increased prevalence of chronic kidney disease and advancements in diagnostic technologies are key growth drivers.
Challenges include rising healthcare costs and the need for regulatory compliance in medical technologies.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
